Fractyl Labs Receives $55M Series E Funding
LEXINGTON, MA, Fractyl Laboratories has raised $55 million in a series E round.
According to MDDI, Fractyl Labs said it will use the proceeds to support the Revita T2Di pivotal clinical trial of Revita DMR (duodenal mucosal resurfacing) for the treatment of patients with type 2 diabetes (T2D).
Fractyl's Revita examines the effect of Fractyl's Revita DMR treatment on glycemic control and insulin requirements.
In June, the firm received FDA approval for the pivotal trial.
The primary endpoint of the study will be the percentage of patients who are able to achieve target glycemic control (HbA1c less than or equal to 7%) without the need for insulin at 24 weeks post procedure, comparing Revita DMR to the sham arm. Secondary endpoints will assess the impact of Revita DMR on additional glycemic, hepatic, and cardiovascular endpoints.
Fractyl's financing was led by new investor Taiwania Capital Management Corporation and included returning investors Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures, and GV.
New investors, Catalio Capital Management, CDIB Venture Capital Corp., and YJ Capital, also participated in the round. Michael Huang, Managing Partner at Taiwania, will join Fractyl's board in conjunction with the financing.
"We welcome our new investors and the continued support of our returning investors, who recognize that we are at a pivotal moment in fundamentally redefining the treatment paradigm for metabolic diseases, including type 2 diabetes and NAFLD/NASH," Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl said in a release. "We look forward to initiating our pivotal U.S. clinical trial later this year."
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about